
    
      Phase III, double-blind, randomised study assessing the efficacy of capivasertib +
      fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced
      (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor
      2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after
      aromatase inhibitor (AI) therapy.
    
  